Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   85 Trials   85 Trials   3645 News 


«12...1718192021222324252627...4546»
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL. (Pubmed Central) -  Jan 14, 2022   
    Novel effective immunotherapies and targeted agents are expected to address unmet needs in adult ALL. This review has summarized recent evidence to determine whether these approaches can lead to the decreased use of chemotherapy among older adults with ALL and result in improved outcomes.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Have any strategies in Ph-like ALL been shown to be effective? (Pubmed Central) -  Jan 14, 2022   
    Furthermore, the encouraging activity of novel therapies such as inotuzumab and blinatumomab in chemo-refractory B-cell ALL has promoted an interest in introducing these agents early in Ph-like ALL management, which may lead to improved cure rates with frontline therapies, sparing more adults from undergoing early allogeneic hematopoietic cell transplantation (HCT). Finally, the high relapse rate in patients with Ph-like ALL, does not necessary correlate with early minimal residual disease (MRD) response, raising the question of consolidation with allogenic HCT in all adults with Ph-like ALL in first complete remission irrespective of MRD response.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Review, Journal:  Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL? (Pubmed Central) -  Jan 14, 2022   
    CD19-targeted immunotherapies such as blinatumomab and chimeric antigen receptor (CAR) T cell therapy have produced remarkable responses in relapsed/refractory (r/r) B-cell ALL, including clearance of minimal residual disease (MRD)...Although there are concerns about older adults tolerating the expected toxicities associated with CAR T cell therapy, which may be life threatening, tailored approaches for prophylactic and pre-emptive interventions combined with utilization of safer CAR T cell platforms may improve tolerability and further extend the use of this promising treatment to older patients with ALL. In this review, we will discuss the progress in immunotherapies for older adults with B-cell ALL and their potential for transforming frontline therapy for newly diagnosed patients.
  • ||||||||||  Gazyva (obinutuzumab) / Roche, Biogen
    Journal:  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. (Pubmed Central) -  Jan 11, 2022   
    The combination of an easily expandable CIK cell effector population with a mAb already in clinical use establishes a tumor antigen-specific redirection strategy that can be rapidly translated into clinical practice, providing an effective therapeutic alternative for B-cell malignancies without any need for genetic modifications. Additionally, the approach can be potentially applied to an extremely vast array of different tumors by simply substituting the targeting mAb.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Washout Time to Avoid Drug-Drug Interaction between Blinatumomab and Busulfan during Hematopoietic Stem Cell Transplant Conditioning. (Salt Palace Convention Center Hall A) -  Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_1373;    
    We did not observe any consistent suppression of Bu CL, instead changes in CL were in opposite directions, indicating no effect of Blina DDI or elevated cytokine levels when Bu was given 5 or 6 days after the last Blina dose. Our findings suggest Blina and its pharmacodynamic effects are washed out, at the latest 5 days after the last Blina dose but suggest PK guided Bu dosing to prevent any potential toxicities.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Non Relapse Mortality(NRM) Form Blinatumomab. Data Fro Faers (Salt Palace Convention Center Hall A) -  Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_1027;    
    There were 2920 total cases with 391 total deaths and 371 total deaths not related to disease progression. NRM remains high at 12%
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal:  Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. (Pubmed Central) -  Jan 7, 2022   
    Tisagenlecleucel was also associated with a lower hazard of death than blinatumomab in every analysis, ranging from 68% to 74% lower hazard of death than with blinatumomab, determined using multiple adjustment approaches (hazard ratios: 0.26-0.32). These findings support the growing body of clinical trial and real-world evidence demonstrating that tisagenlecleucel is an important treatment option for children and young adults with R/R ALL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial primary completion date:  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jan 6, 2022   
    P1,  N=44, Recruiting, 
    These findings support the growing body of clinical trial and real-world evidence demonstrating that tisagenlecleucel is an important treatment option for children and young adults with R/R ALL. Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal, IO biomarker:  Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go. (Pubmed Central) -  Jan 4, 2022   
    Another line of research led to the bispecific antibodies that can enhance the formation of immunological synapse between cancer and cytotoxic T cells (blinatumomab)...There are already some preliminary reports that suggest such constructs would be an achievable goal. In this brief review, we discuss some of the successful preclinical developments in the field and the major challenges that are yet to be addressed.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  ALL2820: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL (clinicaltrials.gov) -  Jan 4, 2022   
    P3,  N=236, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Feb 2024 Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Mar 2021 --> Sep 2021 | Trial primary completion date: Jun 2027 --> Sep 2027
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. (Pubmed Central) -  Jan 1, 2022   
    In this review, we discuss the rapidly evolving paradigms in the treatment of ALL, highlighting both established and effective regimens, as well as promising new therapies that are being evaluated in ongoing clinical trials. We specifically focus on novel combination regimens in both the frontline and salvage settings that are leading to new standards of care in the treatment of ALL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal, CAR T-Cell Therapy:  Bispecific antibodies: An old story with a bright future… with CAR-T cells! (Pubmed Central) -  Dec 31, 2021   
    These anti-tumor effects have been translated into the clinics, especially to treat malignant hemopathies. At last, recently generated bispecific CAR-T cells suggest that the embrace between cell therapy and bispecific antibodies is not over and that we are yet to witness further discoveries enabling these cells to be even more efficient.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Bispecific antibodies targeting CD3 in oncology and hematology (Pubmed Central) -  Dec 31, 2021   
    To date, only blinatumomab have reached market agreements in lymphoid malignancies with constructs targeting CD3exCD19...These successes have relaunched the development of TCE in solid tumors, bringing mixed results so far (notably in terms of tolerance). Still, TCE pave the way to new immunotherapy in tumors considered to be refractory to inhibitors of immune checkpoints such as prostate cancer or colorectal cancer.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Bispecific antibodies in onco-hematology: Applications and perspectives (Pubmed Central) -  Dec 31, 2021   
    The anti-CD3/CD19 antibody blinatumomab is the first in class and have been approved for the treatment of patients with Ph-negative B-cell acute lymphoblastic leukemia...The safety profile of bispecific antibodies is acceptable while limited by neurotoxicity and cytokine-release syndrome. The present review aims to depict the landscape of emerging bispecific antibodies currently in development for hematological malignancies.
  • ||||||||||  Review, Journal:  Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies. (Pubmed Central) -  Dec 27, 2021   
    In recent years, growing evidence suggests that certain small molecule inhibitors, such as BTK inhibitors and PI3K inhibitors, may cause an increased risk of IFI in certain patients. It is imperative to better understand the impact that novel targeted therapies might have on the development of IFIs in this high-risk patient population.
  • ||||||||||  methotrexate IV / Generic mfg.
    PROGRESS IN THE TREATMENT OF ADULT B-CELL PRECURSOR PHILADELPHIA CHROMOSOME-NEGATIVE ALL: RISK ADAPTED TREATMENTS AND NOVEL IMMUNOTHERAPIES () -  Dec 25, 2021 - Abstract #SIE2021SIE_70;    
    The two blinatumomab cycles were given sequentially after early consolidation cycle 3 (high-dose methotrexate and Cytarabine) and late consolidation cycle 6, to all study patients regardless of MRD being assessable...These results are in line with those observed in the front-line GIMEMA LAL2116 protocol for Ph+ ALL patients treated with dasatinib followed by blinatumomab5 .Blinatumomab was also capable of eradicating MRD in Ph-like patients who are usually resistant to chemotherapy programs3...Among these, we have developed a new product based on donor-derived CD19 CAR cytokine induced killer (CIK) cells. These cells are engineered with the Sleeping Beauty transposon and demonstrate a high expansion rate, low toxicity and lead to complete remission in relapsed/refractory B-ALL.11
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Journal:  Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. (Pubmed Central) -  Dec 25, 2021   
    These cells are engineered with the Sleeping Beauty transposon and demonstrate a high expansion rate, low toxicity and lead to complete remission in relapsed/refractory B-ALL.11 No abstract available
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  BET2017: Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Dec 23, 2021   
    P1,  N=19, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | N=13 --> 19 | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Aug 2021 --> Nov 2021